title: Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
abstract: T cell-based cancer immunotherapy relies on advancements made over the last 20 years on the molecular mechanisms underlying the antigenicity of tumors. This review focuses on human tumor antigens recognized by T lymphocytes, particularly the reasons why some are tumor-specific but others are not, and on the immunologic adjuvants used in clinical trials on therapeutic vaccination with defined tumor antigens.
authors.affiliation: de Duve Institute, University of Louvain, Brussels, Belgium.
authors.forename: Teofila
authors.initials: T
authors.lastname: Seremet
authors.forename: Francis
authors.initials: F
authors.lastname: Brasseur
authors.forename: Pierre G
authors.initials: PG
authors.lastname: Coulie
mesh_terms: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D019496:Cancer Vaccines